artivabio
Oncology Therapeutics · Immunology & Inflammation Therapeutics
6open roles
$253kmedian advertised pay
Scaling fasthiring pace, 77 of 100
35 daysmedian time a role stays open
Overview
Artiva Biotherapeutics is a cell therapy company with the ability to produce highly scaled, off-the-shelf, allogeneic NK cell therapies.
How artivabio hires
Truth index
B 75/100
Median time to fill
35 days
Ghost roles
0%
Stale roles
100%
Reposted roles
0%
artivabio scores B on the Alion truth index (A is best, E worst), measured over 3 open roles re-checked against its own hiring board: 0% look like ghost listings, 100% have gone stale and 0% are the same role posted again. Its roles close in a median of 35 days. It measures how much of what this employer publishes turns into a real, finite search - not the employer as a workplace. How the index is computed
Jobs
$260k – $275k per year · In office · Full-Time · 10+ years exp · Bachelor's Degree · United States
Apply
$110k – $135k per year · In office · Full-Time · 3+ years exp · Bachelor's Degree · San Diego
GCP
Life Sciences
Good Clinical Practice
Apply
$190k – $230k per year · In office · Full-Time · 6+ years exp · PhD · United States
Apply
$155k – $190k per year · In office · Full-Time · 6+ years exp · Bachelor's Degree · San Diego
GMP
Apply
$250k – $300k per year · In office · Full-Time · PhD · San Diego
Apply
$265k – $280k per year · In office · Full-Time · 10+ years exp · San Diego
GCP
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$253k
Typical range
$135k – $300k
Open positions
6
6
Jobs
Senior
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 6 | $253k | $135k – $300k |
Highest paying role
Sr. Director/ED, Medical Affairs Medical Communications Publications
$300k
Normalized to USD per year
All salaries at artivabio
By role, level and city, against the market · 6 jobs with pay
Growth
Hiring Momentum
77/100
Scaling fast
Open positions
6
2 opened / 7 closed in 30 days
Median time-to-fill
35 days
faster than 37% of the market
ATS activity
Every ~6 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Industrial Engineering
31% ▼
Biotech
31% ▲
Science & Research
19% ▲
Data Science
6% ▼
Analytics
6% ▼
Public Policy
6% ▼
Activity Timeline
New location: United States
Oct 2026
Added CAPA to stack
Oct 2026
Added ICH Guidelines to stack
Oct 2026
Added FMEA to stack
Oct 2026
Added 21 CFR Part 11 to stack
Oct 2026
Added Flow Cytometry to stack
Oct 2026
Added ELISA to stack
Oct 2026
Added Outlook to stack
Oct 2026
Added Good Clinical Practice to stack
Oct 2026
Added GMP to stack
Oct 2026
Removed Windows from stack
Sep 2026
Tech stack
Technologies named in job postings at artivabio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
27
Postings analysed
13
Stack modernity
67/100
Languages
Python8%
Frameworks & libraries
NumPy8%
Pandas8%
Scikit-learn8%
Django8%
Databases
Google BigQuery8%
PostgreSQL8%
Cloud & platforms
GCP31%
AWS8%
Azure8%
Active Directory8%
Sign in to see how your skills match this stack
Sign In
Full artivabio tech stack
27 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
venBio PartnersVia a fund
EcoR1 CapitalVia a fund
Wellington ManagementVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
SDBJ: Artiva Raises $300M to Fund Phase 3 Trial for RA Cell Therapy
Artiva was featured in San Diego Business Journal following its $300 million financing to support the continued advancement of AlloNK in autoimmune disease. The article discusses the company's planned Phase 3 trial in refractory rheumatoid arthritis and i
Read more
Report
Biotech2050 Podcast: Fred Aslan, Artiva CEO, on Cell Therapy's Next Wave, RA Trials & Scalable NK Platforms
Over the past decade, CAR-T therapies have demonstrated curative potential, while also underscoring how complexity, cost, and infrastructure can limit the number of patients who can be treated. In this episode of the Biotech2050 podcast, Artiva's CEO Fred
Read more
Report
Base to Base Biotech Podcast: Natural Killer Cell Therapy
In rheumatoid arthritis, existing therapies frequently fall short of delivering sustained disease control, despite sequential use of biologic and targeted agents. In a this episode of the 𝗕𝗮𝘀𝗲 𝘁𝗼 𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁, Lisa Guerrettaz, Executive Director,
Read more
Report
SDBJ: Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease
SDBJ: Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease Artiva Biotherapeutics was featured in the San Diego Business Journal highlighting the Company's strategic transition into autoimmune disease and the FDA Fast Track Designation fo
Read more
Report
Inside Precision Medicine: Asked & Answered with Artiva's CMO Dr. Subhashis Banerjee
Inside Precision Medicine spoke with Artiva's Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK in autoimmune disease. In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK through a parallel trial s
Read more
Report
Pharmaceutical Manufacturer Q&A: Artiva Allogeneic NK Cell Therapies for Treating Autoimmune Disease
In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company's mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseas
Read more
Report
GEN: The Body's Delta Force: Natural Killer Cells Re-Emerge
In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advan
Read more
Report
The Bio Report Podcast: Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease
NK cells, part of the innate immune system, serve as the body's first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-th
Read more
Report
In Vivo: Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm
Artiva's President and CEO Fred Aslan, M.D., explores how Artiva is reshaping cell therapy with In Vivo. In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells fo
Read more
Report
Drug Discovery World: Expanding Access to Cell Therapies for Autoimmune Conditions
DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics, about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in th
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
San Diego
San Diego
United States
HQ
Artiva Biotherapeutics
4 open roles 13 posted in 90 days 50-200 est. staff $226k Avg Salary
hires for Biotech
5505 Morehouse Drive, Suite 100, San Diego, California, 92121